Jordi Mones
Overview
Explore the profile of Jordi Mones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jaffe G, Westby K, Csaky K, Mones J, Pearlman J, Patel S, et al.
Ophthalmology
. 2021 Oct;
128(12):e219-e220.
PMID: 34600775
No abstract available.
12.
Ogura Y, Jaffe G, Cheung C, Kokame G, Iida T, Takahashi K, et al.
Br J Ophthalmol
. 2021 Jul;
106(7):994-999.
PMID: 34301613
Purpose: To compare the efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy (PCV) over 96 weeks in the HAWK study. Design: HAWK was a global,...
13.
Colijn J, Liefers B, Joachim N, Verzijden T, Meester-Smoor M, Biarnes M, et al.
JAMA Ophthalmol
. 2021 May;
139(7):743-750.
PMID: 34014262
Importance: Treatments for geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), are currently under development. Understanding the natural course is needed for optimal trial design. Although enlargement...
14.
Wykoff C, Rosenfeld P, Waheed N, Singh R, Ronca N, Slakter J, et al.
Ophthalmology
. 2021 Mar;
128(9):1325-1336.
PMID: 33711380
Objectives: To evaluate clinical characteristics of eyes in which investigator-determined new-onset exudative age-related macular degeneration (eAMD) developed during the FILLY trial. Design: Post hoc analysis of the phase 2 study...
15.
Steinle N, Pearce I, Mones J, Metlapally R, Saroj N, Hamdani M, et al.
Am J Ophthalmol
. 2021 Mar;
227:116-124.
PMID: 33675755
Purpose: To evaluate the effect of select baseline characteristics on geographic atrophy (GA) progression in eyes receiving intravitreal pegcetacoplan or sham. Design: Phase 2 multicenter, randomized, single-masked, sham-controlled trial. Methods:...
16.
Jaffe G, Westby K, Csaky K, Mones J, Pearlman J, Patel S, et al.
Ophthalmology
. 2021 Feb;
128(5):e26-e27.
PMID: 33551285
No abstract available.
17.
Mones J, Srivastava S, Jaffe G, Tadayoni R, Albini T, Kaiser P, et al.
Ophthalmology
. 2020 Nov;
128(7):1050-1059.
PMID: 33207259
Purpose: An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK and...
18.
Rodriguez A, Biarnes M, Coco-Martin R, Sala-Puigdollers A, Mones J
J Ophthalmol
. 2020 Oct;
2020:9457457.
PMID: 33014447
Purpose: This study aims to find out which tool, fundus autofluorescence (FAF) or spectral domain optical coherence tomography (SD-OCT), is more sensitive in detecting retinal pigment epithelium (RPE) demise overlying...
19.
Hilely A, Au A, Freund K, Loewenstein A, Souied E, Zur D, et al.
Br J Ophthalmol
. 2020 Sep;
105(10):1415-1420.
PMID: 32920528
Purpose: To evaluate the various patterns of subretinal fluid (SRF) in eyes with age-related macular degeneration (AMD) in the absence of macular neovascularisation (MNV) and to assess the long-term outcomes...
20.
Jaffe G, Westby K, Csaky K, Mones J, Pearlman J, Patel S, et al.
Ophthalmology
. 2020 Sep;
128(4):576-586.
PMID: 32882310
Purpose: The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York,...